{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:07:33Z","timestamp":1790809653755,"version":"4.1.0"},"reference-count":66,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2017.5094","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T08:00:04Z","timestamp":1504252804000},"source":"Crossref","is-referenced-by-count":13,"title":["Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non\u2011small cell lung cancer: A network meta\u2011analysis"],"prefix":"10.3892","author":[{"given":"Yuanyuan","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Public Health, School of Medicine, Shihezi University, Shihezi, Xinjiang 832002, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, Xinjiang 832002, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangling","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Public Health, School of Medicine, Shihezi University, Shihezi, Xinjiang 832002, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Public Health, School of Medicine, Shihezi University, Shihezi, Xinjiang 832002, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangzhi","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Public Health, School of Medicine, Shihezi University, Shihezi, Xinjiang 832002, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhong","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Public Health, School of Medicine, Shihezi University, Shihezi, Xinjiang 832002, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shugang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Public Health, School of Medicine, Shihezi University, Shihezi, Xinjiang 832002, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxia","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Public Health, School of Medicine, Shihezi University, Shihezi, Xinjiang 832002, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2017,9,1]]},"reference":[{"key":"key20200713142308_b1-etm-0-0-5094","first-page":"178","article-title":"Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong","volume":"20","author":"Lee","year":"2014","journal-title":"Hong Kong Med J"},{"key":"key20200713142308_b2-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40880-015-0006-x","article-title":"Report of cancer incidence and mortality in China, 2011","volume":"24","author":"Chen","year":"2015","journal-title":"China Cancer"},{"key":"key20200713142308_b3-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"12196","DOI":"10.3390\/ijerph121012196","article-title":"High cancer burden in elderly chinese, 2005\u20132011","volume":"12","author":"Li","year":"2015","journal-title":"Int J Environ Res Public Health"},{"key":"key20200713142308_b4-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.lungcan.2011.05.022","article-title":"Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy","volume":"75","author":"Kim","year":"2012","journal-title":"Lung Cancer"},{"key":"key20200713142308_b5-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.3747\/co.22.2566","article-title":"Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib and icotinib in the treatment of non-small-cell lung cancer: A systematic review","volume":"22","author":"Ellis","year":"2015","journal-title":"Curr Oncol"},{"key":"key20200713142308_b6-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11523-015-0376-7","article-title":"The Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for molecularly selected patients with non-small cell lung cancer: A meta-analysis of 30 randomized controlled trials","volume":"11","author":"Liu","year":"2016","journal-title":"Targ Oncol"},{"key":"key20200713142308_b7-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20200713142308_b8-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (iressa survival evaluation in lung cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"key":"key20200713142308_b9-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"key20200713142308_b10-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.lungcan.2011.01.022","article-title":"Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer","volume":"74","author":"Togashi","year":"2011","journal-title":"Lung Cancer"},{"key":"key20200713142308_b11-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/JTO.0b013e3181f77b27","article-title":"Different efficacies of erlotinib and gefitinib in taiwanese patients with advanced non-small cell lung cancer: A retrospective multicenter study","volume":"6","author":"Fan","year":"2011","journal-title":"J Thorac Oncol"},{"key":"key20200713142308_b12-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1200\/JCO.2015.63.4154","article-title":"Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108 L","volume":"34","author":"Urata","year":"2016","journal-title":"J Clin Oncol"},{"key":"key20200713142308_b13-etm-0-0-5094","first-page":"210","article-title":"Clinical research on icotinib hydrochloride in the treatment of advanced non-small cell lung cancer","volume":"28","author":"Xia","year":"2015","journal-title":"J Basic Clin Oncol"},{"key":"key20200713142308_b14-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S1470-2045(13)70355-3","article-title":"Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): A randomised, double-blind phase 3 non-inferiority trial","volume":"14","author":"Shi","year":"2013","journal-title":"Lancet Oncol"},{"key":"key20200713142308_b15-etm-0-0-5094","volume-title":"Evidence-based Medicine","author":"Li","year":"2014"},{"key":"key20200713142308_b16-etm-0-0-5094","first-page":"183","article-title":"The quality assessments for randomized controlled trials","volume":"4","author":"Zeng","year":"2012","journal-title":"Chin J Evid Based Cardiovasc Med"},{"key":"key20200713142308_b17-etm-0-0-5094","first-page":"297","article-title":"The quality assessments for observational study","volume":"4","author":"Zeng","year":"2012","journal-title":"Chin J Evid Based Cardiovasc Med"},{"key":"key20200713142308_b18-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/ajg.2011.301","article-title":"Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer?","volume":"106","author":"Yuhara","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"key20200713142308_b19-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Nati Cancer Inst"},{"key":"key20200713142308_b20-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"key20200713142308_b21-etm-0-0-5094","first-page":"103","article-title":"Result interpretation of network meta-analysis","volume":"15","author":"Yi","year":"2015","journal-title":"Chin J Evidence Based Med"},{"key":"key20200713142308_b22-etm-0-0-5094","first-page":"3444","article-title":"Comparison of the efficacy of gefitinib and erlotinib as a second line treatment for advanced non-small cell lung cancer","volume":"28","author":"Wang","year":"2012","journal-title":"J Practical Med"},{"key":"key20200713142308_b23-etm-0-0-5094","first-page":"282","article-title":"Efficacy and safety of EGFR-TKIs as first-line treatment in 112 elder patients with advanced non-small cell lung cancer","volume":"37","author":"Song","year":"2015","journal-title":"J Dalian Med Univ"},{"key":"key20200713142308_b24-etm-0-0-5094","first-page":"3534","article-title":"Comparation of clinical effects and safety between gefitinib and erlotinib in treatment of patients with NSCLC","volume":"11","author":"Wu","year":"2011","journal-title":"Chin J of Misdiagnostics"},{"key":"key20200713142308_b25-etm-0-0-5094","first-page":"108","article-title":"Comparison of clinical effectiveness of gefitinib and erlotinib on non-small cell lung cancer","volume":"14","author":"Yuan","year":"2015","journal-title":"Sci and Tech of West China"},{"key":"key20200713142308_b26-etm-0-0-5094","first-page":"73","article-title":"Clinical effect of erlotinib on non - small cell lung cancer and its impact on immunoglobulin levels and T-lymphocyte subsets","volume":"23","author":"Qu","year":"2015","journal-title":"Practical J of Cardiac Cerebral Pneumal and Vascular Disease"},{"key":"key20200713142308_b27-etm-0-0-5094","first-page":"174","article-title":"Comparation of the efficacy and care between gefitinib and erlotinib for the patients with NSCLC","volume":"27","author":"Wang","year":"2014","journal-title":"Medical Inform"},{"key":"key20200713142308_b28-etm-0-0-5094","first-page":"446","article-title":"Gefitinib versus erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer","volume":"35","author":"Xie","year":"2015","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"key20200713142308_b29-etm-0-0-5094","first-page":"192","article-title":"The clinical effects and safety of gefitinib for patients with non-small cell lung cancer","volume":"4","author":"Xie","year":"2014","journal-title":"Yiayao Qianyan"},{"key":"key20200713142308_b30-etm-0-0-5094","first-page":"100","article-title":"Clinical effect and pharmacoeconomics of gefitinib and erlotinib in advanced non-small-cell lung cancer","volume":"5","author":"Weng","year":"2015","journal-title":"Chin Med Pharm"},{"key":"key20200713142308_b31-etm-0-0-5094","first-page":"908","article-title":"Effect and cost-efficacy analysis of the second-line treatment of advanced non-small cell lung cancer","volume":"17","author":"Zhang","year":"2012","journal-title":"Chin Clin Oncol"},{"key":"key20200713142308_b32-etm-0-0-5094","first-page":"2273","article-title":"The observation of toxicities for targeted therapy in advanced non-small cell lung cancer","volume":"25","author":"Zhang","year":"2014","journal-title":"Hainan Med J"},{"key":"key20200713142308_b33-etm-0-0-5094","first-page":"579","article-title":"Adverse drug reaction of gefitinib in therapy for patients with advanced non-small cell lung cancer","volume":"19","author":"Chen","year":"2009","journal-title":"Chin J of Hemorheology"},{"key":"key20200713142308_b34-etm-0-0-5094","first-page":"837","article-title":"Clinical effect and pharmacoeconomics of gefitinib and erlotinib in advanced non-small-cell lung cancer","volume":"28","author":"Zhang","year":"2009","journal-title":"Chin J New Drugs Clin Rem"},{"key":"key20200713142308_b35-etm-0-0-5094","first-page":"899","article-title":"Clinical effect and safety of gefitinib and erlotinib second line treatment of lung adenocarcinoma","volume":"31","author":"Zhang","year":"2015","journal-title":"Chin J Clin Pharmacol"},{"key":"key20200713142308_b36-etm-0-0-5094","first-page":"1308","article-title":"The comparison of efficacy between gefitinib and erlotinib for patients with brain metastases from non-small cell lung cancer","volume":"28","author":"Li","year":"2015","journal-title":"Chin J Clin Res"},{"key":"key20200713142308_b37-etm-0-0-5094","first-page":"1028","article-title":"Clinical observation of gefitinib and erlotinib for brain metastases of non-small cell lung cancer","volume":"20","author":"Bai","year":"2015","journal-title":"Chin Clin Oncol"},{"key":"key20200713142308_b38-etm-0-0-5094","article-title":"Clinical observation of 70 patients with brain metastases","author":"Li","year":"2013","journal-title":"Dalian Medical Univ"},{"key":"key20200713142308_b39-etm-0-0-5094","first-page":"285","article-title":"Clinical comparison of erlotinib and gefitinib in non-small cell lung cancer with brain metastases","volume":"22","author":"Zhang","year":"2015","journal-title":"Chin J Cancer Prevent Treat"},{"key":"key20200713142308_b40-etm-0-0-5094","first-page":"203","article-title":"The cost-effectiveness analysis of gefitinib or erlotinib in the treatment of advanced EGFR mutant non-small cell lung cancer patients","volume":"16","author":"Ma","year":"2013","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"key20200713142308_b41-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejca.2012.07.014","article-title":"Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer","volume":"49","author":"Shao","year":"2013","journal-title":"Eur J Cancer"},{"key":"key20200713142308_b42-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/JTO.0000000000000095","article-title":"Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21","volume":"9","author":"Lim","year":"2014","journal-title":"J Thorac Oncol"},{"key":"key20200713142308_b43-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s12032-012-0349-y","article-title":"Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: A retrospective analysis","volume":"30","author":"Yoshida","year":"2013","journal-title":"Med Oncol"},{"key":"key20200713142308_b44-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3904\/kjim.2010.25.3.294","article-title":"Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer","volume":"25","author":"Hong","year":"2010","journal-title":"Korean J Intern Med"},{"key":"key20200713142308_b45-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/1471-2407-9-333","article-title":"Response to gefitinib and erlotinib in non-small cell lung cancer: A retrospective study","volume":"9","author":"Emery","year":"2009","journal-title":"BMC Cancer"},{"key":"key20200713142308_b46-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3892\/etm.2011.383","article-title":"Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations","volume":"3","author":"Wu","year":"2012","journal-title":"Exp Ther Med"},{"key":"key20200713142308_b47-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.lungcan.2010.08.013","article-title":"Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations","volume":"72","author":"Wu","year":"2011","journal-title":"Lung Cancer"},{"key":"key20200713142308_b48-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1002\/cncr.25130","article-title":"Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy","volume":"116","author":"Kim","year":"2010","journal-title":"Cancer"},{"key":"key20200713142308_b49-etm-0-0-5094","first-page":"2056","article-title":"Efficacy and toxicity of ecotinib and gefitinib in the treatment for 28 patients with non-small cell lung cancer who have failed previous chemotherapy","volume":"21","author":"Chen","year":"2012","journal-title":"Chin J New Drugs"},{"key":"key20200713142308_b50-etm-0-0-5094","first-page":"441","article-title":"A phase III study on icotinib hydrochloride for non-small cell lung cancer","volume":"1","author":"Chen","year":"2011","journal-title":"Anti-Tumor Pharmacy"},{"key":"key20200713142308_b51-etm-0-0-5094","first-page":"326","article-title":"Efficacy of icotinib and gefitinib in advanced lung adenocarcinoma with EGFR mutation","volume":"36","author":"Cui","year":"2015","journal-title":"Acad J Chin Pla Med School"},{"key":"key20200713142308_b52-etm-0-0-5094","first-page":"556","article-title":"Icotinib in treatment for 49 patients with non small cell lung cancer in epidermal growth factor receptor mutant","volume":"34","author":"Cui","year":"2015","journal-title":"Chin J New Drugs Clin Rem"},{"key":"key20200713142308_b53-etm-0-0-5094","first-page":"175","article-title":"The observation and care of EGFR-TKIs therapy for patients with advanced non-small cell lung cancer","volume":"27","author":"Liu","year":"2014","journal-title":"Med Inf"},{"key":"key20200713142308_b54-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1021\/jm00199a019","article-title":"Clinical observation of icotinib for non-small cell lung cancer","volume":"21","author":"Lin","year":"2014","journal-title":"Chin J Prim Med Pharm"},{"key":"key20200713142308_b55-etm-0-0-5094","first-page":"94","article-title":"Clinical observation of icotinib and gefitinib in first-line therapy for advanced non-small cell lung cancer","volume":"12","author":"Xu","year":"2015","journal-title":"J Hunan Normal Univ (Med Sci)"},{"key":"key20200713142308_b56-etm-0-0-5094","first-page":"8","article-title":"Clinical observation of icotinib hydrochloride and erlotinib in the treatment of patients with advanced lung cancer who failed previous chemotherapy","volume":"33","author":"Huang","year":"2014","journal-title":"Chin Foreign Med Treat"},{"key":"key20200713142308_b57-etm-0-0-5094","first-page":"34","article-title":"The comparison of efficacy between icotinib and erlotinib for patients with advanced non-small cell lung cancer","volume":"55","author":"Sun","year":"2015","journal-title":"Shandong Med J"},{"key":"key20200713142308_b58-etm-0-0-5094","first-page":"1032","article-title":"Comparison of clinical effects and safety between icotinib and erlotinib in treatment of advanced non-small cell lung cancers","volume":"17","author":"Zhang","year":"2015","journal-title":"J of Chin Phy"},{"key":"key20200713142308_b59-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"e0142500","DOI":"10.1371\/journal.pone.0142500","article-title":"The efficacy and safety of icotinib in patients with advanced non-small cell lung cancer previously treated with chemotherapy: A single-arm, multi-center, prospective study","volume":"10","author":"Hu","year":"2015","journal-title":"PLoS One"},{"key":"key20200713142308_b60-etm-0-0-5094","first-page":"538","article-title":"Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer","volume":"9","author":"Shao","year":"2010","journal-title":"Discov Med"},{"key":"key20200713142308_b61-etm-0-0-5094","first-page":"81","article-title":"Structural bioinformatics-based identification of EGFR inhibitor gefitinib as a putative lead compound for BACE","volume":"83","author":"Niu","year":"2014","journal-title":"Chem Biol Orug Des"},{"key":"key20200713142308_b62-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"e273","DOI":"10.1200\/JCO.2009.26.5496","article-title":"Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity","volume":"28","author":"Takeda","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20200713142308_b63-etm-0-0-5094","first-page":"121","article-title":"The new choice for non-small cell lung cancer patients - iootinib hydrochloride","volume":"32","author":"Zhang","year":"2013","journal-title":"J Pharmaceuti Res"},{"key":"key20200713142308_b64-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.ctrv.2014.06.010","article-title":"Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions","volume":"40","author":"Peters","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"key20200713142308_b65-etm-0-0-5094","doi-asserted-by":"publisher","first-page":"e55128","DOI":"10.1371\/journal.pone.0055128","article-title":"Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: A systematic review and meta-analysis","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS one"},{"key":"key20200713142308_b66-etm-0-0-5094","first-page":"232","article-title":"The severe adverse events and prevention measures for erlotinib","volume":"19","author":"Li","year":"2010","journal-title":"Chin J Pharmacoepidemiol"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T13:23:34Z","timestamp":1594646614000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2017.5094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,1]]},"references-count":66,"URL":"https:\/\/doi.org\/10.3892\/etm.2017.5094","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,1]]}}}